Article

Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of Growth Hormone Releasing Hormone (GHRH)

2025-07-07

Abstract excerpt

Heart failure (HF) with preserved ejection fraction (HFpEF) carries a high mortality and remains a major therapeutic challenge. Effective, targeted therapies capable of reversing HFpEF pathophysiology are urgently needed. We previously demonstrated that activation of the cardiac growth hormone-releasing hormone (GHRH) pathway using high potency synthetic agonists of GHRH (GHRH-agonists: MR-356 and MR-409) improves...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 7634caf9-2f63-544e-93a5-b1e107cd4b44
DOI: 10.1101/2025.07.03.662389

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cardiomyocyte-specific expression of HIF-1α mediates the cardioprotective effects of Growth Hormone Releasing Hormone (GHRH)DOI 10.1101/2025.07.03.662389Read

Synthetic Growth Hormone-Releasing Hormone Agonist as Novel Treatment for Heart Failure with Preserved Ejection FractionSemantic proximity Read

Therapeutic potential of Relaxin-2 in Heart Failure with preserved Ejection Fraction (HFpEF)Semantic proximity Read

Gene expression profiling of hypertrophic cardiomyocytes identifies new players in pathological remodellingSemantic proximity Read

Targeting <i>Runx</i> 1 protects against heart failure with preserved ejection fractionSemantic proximity Read

Exploiting the hypoxia sensitive non-coding genome for organ-specific physiologic reprogramming.Semantic proximity Read

Combining three independent pathological stressors induces a heart failure with preserved ejection fraction phenotype.Semantic proximity Read

Conditional HIF-1α Expression Produces a Reversible CardiomyopathySemantic proximity Read

An inducible genetic model of chronic hypoxic signaling in cardiomyocytes precipitates severe cardiomyopathy and remodelingSemantic proximity Read

Targeting Metabolic Dysfunction and Inflammation with Sotagliflozin Reverses Diastolic Dysfunction in Experimental HFpEFSemantic proximity Read

Ulacamten: A Novel, RLC-Targeting Cardiac Myosin Inhibitor for Potential Treatment of Cardiac Hypercontractility, Including HFpEFSemantic proximity Read

Aerobic exercise-induced up-regulation of HIF-1α ameliorates heart failure by regulating MCT1 and MPC1 expressionSemantic proximity Read

Metabolic reprogramming via PPARα signaling in cardiac hypertrophy and failure: From metabolomics to epigeneticsSemantic proximity Read